21/46US=58 / Câncer
Krämer A. Centrosomes in checkpoint responses. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 53-67. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6.

CENTROSSOMAS NAS RESPOSTAS CHECKPOINT; CENTROSSOMA; DANOS NO DNA; CHECK-POINT; CHK1; PERICENTRIN; MICROCEFALINA; CDC25; SINDROME SECKEL; MICROCEFALIA; AMPLIFICACAO CENTROSSOMA; CATASTROFE MITOTICA

22/46US=58 / Câncer
Lee MH, Yeung SCJ, Yang HY. Interplay of 14-3-3 family of proteins with DNA damage-regulated molecules in checkpoint control. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 69-80. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6.

FAMILIA DE PROTEINAS COM 14-3-3; DANOS AO DNA; RESPOSTA CHECKPOINT; 14-3-3; AKT; MDM2; P53; DANOS NO DNA

23/46US=58 / Câncer
Nakanishi M. Chromatin modifications and orchestration of checkpoint response in cancer. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 83-93. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6.

MODIFICACOES DE CROMATINA; ORQUESTRACAO DE RESPOSTA; CONTROLE EM CANCER; CHK1; CHK2; P53; REPLICACAO DO DNA

24/46US=58 / Câncer
Kaina B, Roos WP, Christmann M. DNA damage response and the balance between cell survival and cell death. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 95-108. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6.

DANOS NO DNA; SOBREVIVENCIA CELULAR; MORTE CELULAR; CHECKPOINTS; CICLO CELULAR; RESPOSTA A DANOS DO DNA; REPARACAO DO ADN; P53; APOPTOSE; RECEPTORES DE MORTE; FAS; CAIXA ELETRONICO; ATR; DROGAS ANTICANCER

25/46US=58 / Câncer
Pentimalli F, Cito L, Giordano A. Dysfunction of the RB retinoblastoma gene in cancer. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 109-22. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6.

DISFUNCAO DO GENE; RETINOBLASTOMA RB NO CANCER; RETINOBLASTOMA; FAMILIA RB; SUPRESSORES TUMORAIS; CICLO CELULAR; G1-S DE TRANSICAO; CHECKPOINTS; E2F

26/46US=58 / Câncer
Alao JP. G1 phase cyclins in cancer development and progression. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 123-53. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6.

FASE G1; CICLINAS EM CANCER; CICLO CELULAR; FASE G1; CICLINA D1; CICLINA E; CANCER; ONCOGENE; UBIQUITINA; PROTEASSOMA 26S; TERAPIA DO CANCER

27/46US=58 / Câncer
Friedenson B. The BRCA1/2 pathway prevents some leukemias and lymphomas in addition to breast/ovarian cancers: malignancies that overcome checkpoint controls. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 155-68. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6.

BRCA1; BRCA2; REPARACAO DO ADN; LEUCEMIAS; LINFOMAS; LINFOMA DE CELULAS DO MANTO; LEUCEMIA MIELOIDE AGUDA

28/46US=58 / Câncer
Post SM, Quinás-Cardama A, Lozano G. Regulation of p53 activity and associated checkpoint controls. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 171-88. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6.

P53; MDM2; P19; TUMORIGENESE; CANCER; RAS; CICLO CELULAR; RB; CICLINA; CDK

29/46US=58 / Câncer
Eastman A. The importance of p53 signaling in the response of cells to checkpoint inhibitors. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 189-98. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6.

DANOS NO DNA; PARADA DO CICLO CELULAR; P53; P21; CICLINA B; CHK1 INIBIDORES; UCN-01; INIBIDORES DA TOPOISOMERASE II; ANALOGOS DE NUCLEOSIDOS

30/46US=58 / Câncer
Siddik ZH. Targeting p21-dependent pathways for cell death in cancer therapy. In: ___. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 199-213. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6.

DANOS NO DNA; P21; CICLINA DEPENDENTE DE QUINASE; G1 RESPOSTA CHECKPOINT; PARADA DO CICLO CELULAR; TRANSATIVACAO; PARADA DO CICLO GENE

31/46US=58 / Câncer
Le XF, Bast Junior RC. p27Kip1 as a biomark and target for treatment of cancer. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 215-33. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6.

P27KIP1; CICLO CELULAR; SUPRESSOR DE TUMOR; TERAPIA ALVO; TRASTUZUMAB

32/46US=58 / Câncer
Pevarello P, Bischoff JR, Mercurio C. Targeting cyclin-dependent kinases with small molecular inhibitors. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 235-44. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6.

CICLINA DEPENDENTE DE QUINASE; INIBIDOR DE MOLECULA PEQUENA; SELETIVIDADE; DE MULTI-ALVO; ENSAIOS CLINICOS

33/46US=58 / Câncer
Zhang H, Xiao Z, Sowin T. ChK1 and ChK2 as checkpoint targets. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 245-59. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6.

CHK1; CHK2; INIBIDORES; PARADA DO CICLO CELULAR; REVOGACAO DA RESPOSTA CHECKPOINT; CHEMOPROTECTION; BIOMARCADORES PREDITIVOS

34/46US=58 / Câncer
Rudolph J. Targeting Cdc25 phosphatases in cancer therapy. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 261-9. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6.

CDC25 FOSFATASE; CICLO CELULAR; CANCER; AGENTES ANTI-PROLIFERATIVOS

35/46US=92 / Biol/Mol
Dupré A, Gautier J. DNA damage response, signalling pathways, and tumorigenesis: overview of the DNA damage checkpoint. In: Gewirtz DA, Holt SE, Grant S. Apoptosis, senescence and cancer. 2 ed. New Jersey: Humana Press, 2007. p. 193-221. (Cancer Drug Discovery and Development) ISBN 978-1-58829-527-9.

ATM; ATR; CHECKPOINTS; REPLICA; CADEIA SIMPLES DE DNA; REPARO DE QUEBRA DE DUPLA FITA DO DNA

36/46US=409 / Tese/FAP
Heredia FF. Estudo de proteínas relacionadas ao fuso mitótico (AURORA A e AURORA B) e ponto de checagem mitótico (CDC20 e MAD2L1) em pacientes portadores de Síndrome mielodisplásica. [Mitotic spindle (AURORA A e AURORA B) and mitotic checkpoint (CDC20 and MAD2L1) related protein study in patients with myelodysplastic syndrome]. São Paulo, 2012. 144 p. Tese(Doutorado/Dinter)-Programa de Pós Graduação Interistitucional em Oncologia da Fundação Antônio Prudente/Escola Cearense de Oncologia.

Disponível em: http://accamargo.phlnet.com.br/Doutorado/2012/FabiolaHeredia/FabiolaHeredia.pdf

Curriculum Lattes

SINDROMES MIELODISPLASICAS; EXPRESSAO GENICA; FUSO MITOTICO

37/46US=856 / Tese/FAP
Ribeiro ARG. Impacto prognóstico de marcadores do ciclo celular em pacientes com carcinoma de ovário. [Prognostic impact of cell cycle markers in ovarian cancer patients]. São Paulo, 2020. 101 p. Dissertação(Mestrado)-Fundação Antonio Prudente.

Disponível em: http://accamargo.phlnet.com.br/MESTRADO/2020/ARGRibeiro/ARGRibeiro.pdf

Curriculum Lattes

CARCINOMA SEROSO; NEOPLASIAS OVARIANAS; CICLINA E; BEVACIZUMABE; BIOMARCADORES TUMORAIS; PROGNOSTICO

38/46US=887 / Tese/FAP
Santos IP. Caracterização do perfil imune celular e solúvel de pacientes com melanoma metastático respondedores ou não à imunoterapia com inibidores de checkpoint. [Characterization of the cellular and soluble immune profile of patients with metastatic melanoma submitted to treatment with immune checkpoint inhibitors]. São Paulo, 2020. 49 p. Dissertação(Mestrado)-Fundação Antonio Prudente.

Disponível em: http://accamargo.phlnet.com.br/MESTRADO/2020/IPSantos/IPSantos.pdf

Curriculum Lattes

MELANOMA; QUIMIOCINA CXCL9; IMUNOTERAPIA; ESTUDOS PROSPECTIVOS

39/46US=896 / Tese/FAP
Meduna RR. Estudo sobre terapia de ablação por radiofrequência combinado a inibidores de checkpoint do sistema imune em um modelo murino de carcinoma de células renais. [Study on radiofrequency ablation therapy combined with immune checkpoint inhibitors in a murine model of renal cell carcinoma]. São Paulo, 2021. 69 p. Dissertação(Mestrado)-Fundação Antonio Prudente.

Disponível em: http://accamargo.phlnet.com.br/MESTRADO/2021/RRMeduna/RRMeduna.pdf

Curriculum Lattes

CARCINOMA DE CELULAS RENAIS; SISTEMA IMUNITARIO; ABLACAO POR RADIOFREQUENCIA; CAMUNDONGOS

40/46US=928 / Tese/FAP
Saito AO. Correlação entre os desfechos do tratamento com nivolumabe e a resposta imune e infamatória em pacientes portadores de melanoma e câncer de pulmão. [Correlation between nivolumab treatment outcomes and immune and inflammatory response in melanoma and lung cancer patients]. São Paulo, 2021. 92 p. Dissertação(Mestrado)-Fundação Antonio Prudente.

Disponível em: https://accamargo.phlnet.com.br/MESTRADO/2021/AOSaito/AOSaito.pdf

CANCER DE PULMAO; MELANOMA; NEOPLASIAS PULMONARES; CANCER DE PULMAO DE CELULAS NAO PEQUENAS; CARCINOMA PULMONAR DE CELULAS NAO PEQUENAS; NIVOLUMABE

Primeira | Anterior | Próxima | Última